

References

- Acharya S, Matino D, Mahlangu J, et al. Marstacimab, an anti-tissue factor pathway inhibitor, in participants with hemophilia A or B, with and without inhibitors: An integrated safety analysis. *Blood*. 2023;142(Suppl 1):3980. doi:10.1182/blood-2023-174682
- Ar MC, Balkan C, Kavakli K. Extended half-life coagulation factors: A new era in the management of hemophilia patients. *Turk J Haematol*. 2019;36(3):141-154. doi:10.4274/tjh.galenos.2019.2018.0393
- Castaman G, Peyvandi F, De Cristofaro R, Pollio B, Di Minno DMN. Mild and moderate hemophilia A: Neglected conditions, still unmet needs. *J Clin Med*. 2023;12(4):1368. doi:10.3390/jcm12041368
- Centers for Disease Control and Prevention. Hemophilia. Accessed September 13, 2024. <https://www.cdc.gov/hemophilia/>
- Ellsworth P, Ma A. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates? *Hematology Am Soc Hematol Educ Program*. 2021;2021(1):219-225. doi:10.1182/hematology.2021000253
- Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. *J Comorb*. 2011;1:51-59. doi:10.15256/joc.2011.1.2
- Lentz SR, Chowdary P, Gil L, et al. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. *J Thromb Haemost*. 2024;22(4):990-1000. doi:10.1016/j.jtha.2023.12.016
- Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. *J Blood Med*. 2014;5:207-218. doi:10.2147/JBM.S50644
- Lund J, Ostergaard H, Greisen PJ, et al. A novel FVIIIa-mimetic bispecific antibody, Mim8, enhances FIXa proteolytic activity while allowing for efficient, lipid-dependent assembly with FX [abstract]. *Res Pract Thromb Haemost*. 2020;4(Suppl 1):580 [abstract PB1147]. JL, Morales JC, et al. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. *Br J Haematol*. 2023;200(2):240-248. doi:10.1111/bjh.18495
- Mahlangu J, Kaczmarek R, von Drygalski A, et al for the GENER8-1 Trial Group. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. *N Engl J Med*. 2023;388(8):694-705. doi:10.1056/NEJMoa2211075
- Mancuso ME, Matsushita T, Chowdary P, et al. LB 01.5- Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study. Presented at: International Society on Thrombosis and Haemostasis; Bangkok, Thailand; June 23, 2024.
- Matino D, Acharya S, Palladino A, et al. Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: Results from the phase 3 Basis trial. *Blood*. 2023;142(Suppl 1):285. doi:10.1182/blood-2023-181263
- Matsushita T, Shapiro A, Abraham, A, et al; for the Explorer7 Investigators. Phase 3 trial of concizumab in hemophilia with inhibitors. *N Engl J Med*. 2023;389(9):783-794. doi:10.1056/NEJMoa2216455

Overcoming the Hurdles: Advances in the Management of Hemophilia



- Miesbach WA, Recht M, Key NS, Sivamurthy K, Monahan PE, Pipe SW. Durability of factor IX activity and bleeding rate in people with severe or moderately severe hemophilia B after 5 years of follow-up in the phase ½ study of AMT-060, and after 3 years of follow-up in the phase 2b and 2 years of follow-up in the phase 3 studies of etranacogene dezaparvovec (AMT-061). *Blood*. 2022;140(Suppl 1):4913-4914. doi:10.1182/blood-2022-166810
- Miesbach W, Schwäble J, Müller MM, Seifried E. Treatment options in hemophilia. *Dtsch Arztebl Int*. 2019;116(47):791-798. doi:10.3238/arztebl.2019.0791
- Morfini M, Gherardini S. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. *Ther Adv Hematol*. 2018;9(6):149-162. doi:10.1177/2040620718774258
- Nathwani AC. Gene therapy for hemophilia. *Hematology Am Soc Hematol Educ Program*. 2022;2022(1):569-578. doi:10.1182/hematology.2022000388
- National Bleeding Disorders Foundation. Hemophilia A. Published 2024. Accessed September 13, 2024. <https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-a>
- National Bleeding Disorders Foundation. Hemophilia B. Published 2024. Accessed September 13, 2024. <https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-b>
- National Bleeding Disorders Foundation. MASAC Document 267 – MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. Published April 27, 2022. Accessed September 13, 2024. <https://www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-267-masac-recommendation-concerning-prophylaxis-for-hemophilia-a-and-b-with-and-without-inhibitors>
- National Bleeding Disorders Foundation. MASAC Document 268 – Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors. Published April 27, 2022. Accessed September 13, 2024. <https://www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors>
- O'Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. *Health Qual Life Outcomes*. 2018;16(1):84. doi:10.1186/s12955-018-0908-9
- Persson P, Amstrup AB, Coester HV, Matytsina I, Bas S. Mim9, a novel factor VIIIa mimetic bispecific antibody, show favorable safety and pharmacokinetics in healthy adults. *Res Pract Thromb Haemost*. 2023;7(6):102181. doi:10.1016/j.rpth.2023.102181
- Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. *N Engl J Med*. 2023;388(8):706-718. doi:10.1056/NEJMoa2211644
- Rezende SM, Neumann I, Angchaisuksiri P, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology. *J Thromb Haemost*. 2024;22(9):2629-2652. doi:10.1016/j.jtha.2024.05.026
- Srivastava A, Rangarajan S, Kavakli, et al. Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multi-centre, open-label,

Overcoming the Hurdles: Advances in the Management of Hemophilia



randomized, phase 3 trial. *Lancet Haematol.* 2023;10(5):e322-e332. doi:10.1016/S2352-3026(23)00037-6

Srivastava A, Santagostino E, Dougall A, et al; for the WFH Guidelines for the Management of Hemophilia panelists and co-authors. *Haemophilia.* 2020;26(Suppl 6):1-158. doi:10.1111/hae.14046

von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. *N Engl J Med.* 2023;388(4):310-318. doi:10.1056/NEJMoa2209226

Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomized phase 3 trial. *Lancet.* 2023;401(10386):1427-1437. doi:10.1016/S0140-6736(23)00284-2